Compare CDW Corp. (CDW) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CDW Corp. vs Novo Nordisk A/S — how do they compare? CDW Corp. trades at $134.02 (market cap $16.92B), while Novo Nordisk A/S trades at $46.01 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 12.3× CDW Corp.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| CDW | NVO | |
|---|---|---|
Market Cap | $16.92B | $207.85B |
Sector | Technology | Health |
52-Week High | $170.77 | $63.98 |
52-Week Low | $99.30 | $35.29 |
Enterprise Value | $22.52B | $222.55B |
Dividend Yield | 1.86% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CDW trades at $136.43, up 0.46% with mixed technical signals showing bearish overall momentum but bullish moving averages. The company reported strong Q2 2026 results with earnings beating estimates at $2.91 per share and revenue growth of 10% year-over-year, though margin compression remains a concern. Analyst consensus remains strongly bullish with 12 buy ratings and a $148.67 price target, representing 9% upside potential from current levels.
CDW benefits from strong AI infrastructure demand and consistent dividend payments, but faces margin pressure and CFO transition risks. The stock offers attractive valuation with P/E of 16.27 and P/S of 0.75, though high debt levels and competitive pressures warrant monitoring. Near-term catalysts include Q3 earnings and continued AI-driven infrastructure spending.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
